NASDAQ: ITRM
Iterum Therapeutics PLC Stock Ownership - Who owns Iterum Therapeutics?

Insider buying vs selling

Have Iterum Therapeutics PLC insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Michael W. DunneDirector2025-11-186,000$0.37
$2.19kBuy
Michael W. DunneDirector2025-08-0815,000$0.72
$10.86kBuy

1 of 1

ITRM insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ITRM insiders and whales buy or sell their stock.

ITRM Shareholders

What type of owners hold Iterum Therapeutics PLC stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP22.07%11,651,597$2.12MInsider
Brenton Karl Ahrens3.28%1,733,580$315.51kInsider
Canaan X LP3.28%1,733,170$315.44kInsider
James Healy3.28%1,732,668$315.35kInsider
Patrick J. Heron2.93%1,547,322$281.61kInsider
Vijay K. Lathi2.76%1,456,303$265.05kInsider
Sofinnova Venture Partners IX LP2.32%1,226,514$223.23kInsider
Shahzad Malik1.64%868,161$158.01kInsider
Apollon Financial LLC1.19%630,250$114.71kInstitution
Ronald Hunt0.68%359,366$65.40kInsider

1 of 3

ITRM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ITRM3.16%43.21%Net Buying
INAB14.08%85.92%Net BuyingNet Buying
RNAZ0.11%99.89%
CDIO1.68%98.32%
IMNN4.60%95.40%Net Buying

Iterum Therapeutics Stock Ownership FAQ

Who owns Iterum Therapeutics?

Iterum Therapeutics (NASDAQ: ITRM) is owned by 3.16% institutional shareholders, 43.21% Iterum Therapeutics insiders, and 53.63% retail investors. Ra Capital Management LP is the largest individual Iterum Therapeutics shareholder, owning 11.65M shares representing 22.07% of the company. Ra Capital Management LP's Iterum Therapeutics shares are currently valued at $1.99M.

If you're new to stock investing, here's how to buy Iterum Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.